A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)

• Status: Completed
• Trial end date: 2017-08-04
• Target enrollment: 0
• Participant gender: All

Summary

A study to identify factors that are associated with improved effectiveness in pharmacologic therapy of Overactive Bladder, from the patient perspective primarily measured by OAB-Q-SF (Overactive Bladder Questionnaire Short Form)

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Scientific & Medical Affairs, Inc.
• Treatments: Mirabegron; Muscarinic Antagonists; Oxybutynin

Criteria

Inclusion Criteria:

• Diagnosed with OAB (with or without urgency incontinence) by the treating HCP, with symptoms for at least three months prior to study enrollment

• Initiating a new course of treatment with mirabegron or antimuscarinic medication (including patch formulation) for OAB, which may be first course of any treatment for OAB, restart or switch from one drug to another

• Willing and able to complete PRO questionnaires with minimal assistance

Exclusion Criteria:

• Current participation in clinical trials of OAB

• Use of more than one OAB medication at time of enrollment

• Patients whose OAB has been treated with onabotulinumtoxinA, sacral neuromodulation, percutaneous tibial nerve stimulation, external beam radiation (XRT), stents, surgery, or intermittent catheterization prior to or at time of enrollment

• Neurologic conditions associated with OAB symptoms

• Patients residing in a nursing home